A global pharmaceutical company is looking to form partnerships with small biotech companies using a variety of structures depending on the needs of the opportunity, including licensing, development partnerships, co-marketing, and acquisitions.  Partnerships may also involve in-kind services.  The firm works with partners worldwide.

The firm is currently looking opportunistically at novel therapeutic assets.  While the firm will consider assets in any indication area, immuno-oncology is an area of high interest; the firm is also particularly interested in other areas of immunology and in inflammation, metabolic disease (particularly type 2 diabetes), fibrosis and hypertension. The firm is open to any type of modality, including small molecules, biologics or cell therapies. The firm also has some interest in companion diagnostics and means of selecting suitable patients or monitoring patients. The firm will work with companies at any stage of development, from very early discoveries through to market.

The firm does not work with companies pursuing incremental innovations; the firm only partners on novel, breakthrough technologies, such as new molecules or new targets. The firm is interested in assets in which the mechanism of action is understood, and it is preferred that the target or pathway of the asset is validated. The firm is interested in assets that have been shown to have an unambiguous advantage, and which can create value for patients and payers.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A US based Venture Capital firm is currently looking to make investments from a $125 million with up to 20% of the committed capital going to seed and early stage companies and projects. The firm typically invests between $2 and $4 million initially and $6 million to 10$ million over the lifetime of the investment. Investments are generally in the form of milestone based equity tranches, however the firm also has experience in working with convertible notes. The firm is looking to make 4-6 allocation in the next 6-9 months throughout the United States however they are focused on companies in the Southeast.

The firm is currently looking for early stage companies in the Therapeutics, Diagnostics, Medical Technology and HealthCare IT spaces. In the Therapeutics space the firm is opportunistic in terms of subsector but is most interested in indications of Ophthalmology, Cardiovascular, Pulmonary, Anti-Infectives, Metabolic Disorders, Renal Diseases, Oncology, Immunology, Dermatology, and Orphan Diseases. For companies developing therapeutics the firm is looking for companies primarily with a lead product in preclinical trials although they will consider companies with products having recently entered Phase I. The firm also has generally stayed away from and is not currently seeking companies working with Regenerative Medicine and Wound Care.  In the Medical Technology space the firm strongly prefers that the company have at least have an early prototype of their product and the firm is opportunistic in terms of device subsector.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A family office based in the US is interested in therapeutic, diagnostic, medical device, or healthcare IT companies located throughout the Mid-west. The firm is looking to make 5 more allocations this year with the average investment size around $1 million dollars.

The firm is interested in early stage therapeutics and generally participates in Series A and Series B rounds. The firm will also consider PMA, 510K, and software enabled medical devices in the development, clinical, or on the market stage. The firm does not have a revenue requirement. The firm will also consider healthcare IT, lab equipment, and drug development enabling tech. The firm will invest in orphan diseases, depending on the opportunity, but it is not their primary concern. There are no specific indications of interest.

The firm takes a hands on approach to investing and looks for an experienced, knowledgeable management team that is easy to work with and open to advice.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A large pharmaceutical company based in the US is looking to make strategic investments in therapeutic assets.  The firm uses a variety of partnership structures on a case by case basis, but typically focuses on acquiring or in-licensing assets.  The firm is interested in partnering with biotech companies worldwide.

The firm’s partnering is currently focused on oncology (including both solid tumors and liquid tumors), liver diseases (particularly NASH and fibrosis), inflammatory diseases, and cures for infectious disease (particularly cures for hepatitis B and HIV; vaccines will also be considered). The firm is interested in both small molecule and biologic technologies, but is generally not interested in cell therapies.

While the firm may consider assets at any stage, the firm typically works with companies at the late phase I-early phase II stage, and in the oncology field prefers that companies have some human proof of concept data. Partnerships in the infectious disease field may be formed at an earlier stage, prior to human clinical trials.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A large Chinese conglomerate with approximately USD 50 billion AUM makes direct investments into early stage healthcare IT space via a specialized corporate VC fund. The fund can invest anywhere from US$ 1 million up to $50 million, depending on the deal. Operating from its headquarter in Shanghai, China with an additional office in San Francisco, the firm is currently seeking opportunities in China and the United States.

Within healthcare IT, the firm focuses on consumer-facing mobile and internet companies with large market potential. Examples include telemedicine and patient-doctor interface than lower healthcare costs; data and specimen management systems that improves healthcare workflow; and consumer-oriented biomarker and molecular diagnostic tools. The firm is interested in technologies that can be applied to the Chinese market; however this is not a requirement for investment.

For overseas opportunities, the firm is interested in highly reputable management teams with strong record of success. The firm typically acts as lead investor in a financing round and seeks a board seat after investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A venture capital firm based in the western United States is currently seeking new investment in the healthcare space. The firm has manages approximately $4 billion in total assets and the current venture fund size is $325million. The firm seeks to invest in companies targeting those sectors: consumer applications and services, enterprise infrastructure and apps, and big-bet disruptive technologies. The firm invests in companies in various stages, however it generally invests in venture rounds. The typical investment size ranges from $5 million to $10million.The firm looks to be a lead investor and also co-invests with others for large investments. The firm seeks to invest in companies based in the US.

In the life sciences, the firm is seeking to invest in the healthcare IT, m-Health, diagnostics and selective medical device companies. The firm is not interested in drug development companies. For healthcare IT, the firm invests in companies developing software, solutions and analytical platforms targeting pharma, healthcare providers and consumers. For diagnostics, the firm prefers to invest in genomics and low-risk diagnostic devices. For devices, the firm considers companies with a clear regulatory pathway. In terms of stage of development, the firm focuses on investments in series A round, but it also invests in seed and growth stages, depending on the opportunity. Historically, the firm was active in companies developing drug discovery platform, gene sequencing equipment, synthetic biology, human gene-phenotype database and blood-testing platforms.

The firm invests in privately held life science companies with experienced management teams and innovative technologies. The firm looks to take a board seat post-investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A venture capital firm that was founded in 2008 based in Europe with an additional office in New York City manages €176 million in total assets across two funds. The firm recently held a first close of its second fund at €103 million. The firm typically makes equity investment into early-stage life science companies. The typical investment size ranges from €0.5million-€7million ($0.7million-$10million). The second fund looks to make 10 to 15 investments. The firm generally invests in companies based in the US and Europe.

The venture capital firm is currently looking for new investment opportunities in the life science space. The firm focuses on Therapeutics, Diagnostics and Medical Devices sectors. The firm is very opportunistic in terms of subsectors and indications, and it is most interested in companies in pre-clinical and clinical stages. In the past, the firm was active in therapeutic and diagnostic companies developing drug delivery and gene therapy technologies. The firm was also active in device companies developing single use devices and non-active implantable devices.

The firm primarily invests in private companies with experienced management teams, but it will also consider public companies, depending on the opportunity. The firm seeks to take a board seat in its portfolio companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.